Recursion Pharmaceuticals, Inc. reported $55M of revenue over the trailing twelve months, −15% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $55M (to Q2 2026). Net income: −$519M, trailing twelve months to Q2 2026. Free cash flow: −$352M, trailing twelve months to Q2 2026. Operating margin: −1844%, trailing twelve months to Q2 2026.

RXRXRecursion Pharmaceuticals, Inc.

Healthcare

$4.36-11% 1Y

$4.36

$2.8452 weeks$6.79

RXRX as reported

Recursion Pharmaceuticals, Inc. reported $55M of revenue over the trailing twelve months, −15% on the year before. 10 reported series are charted on this page, each one as filed.

$55M

Revenue, trailing twelve months · to Q2 2026 · −15% against the twelve months before

Net income: −$519M
Net income · −20% year on year · trailing twelve months to Q2 2026
Free cash flow: −$352M
Free cash flow · −11% year on year · trailing twelve months to Q2 2026
Operating margin: −1844%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RXRX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$55M	−15%	Q2 2026
Net income	−$519M	−20%	Q2 2026
EPS	−$1.00	−45%	Q2 2026
Gross margin	−67%	n/a	Q2 2026
Operating margin	−1844%	n/a	Q2 2026
Net margin	−1741%	n/a	Q2 2026
ROE	−59%	n/a	Q2 2026
ROA	−45%	n/a	Q2 2026
ROIC	−124%	n/a	Q2 2026
Free cash flow	−$352M	−11%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.